How did ELTX's operating expenses trend in Q4 2024 compared to previous quarters?

Elicio Therapeutics' operating expenses for Q4 2024 are not currently available. However, the company's financial results for the quarter ended December 31, 2024, reported a quarterly adjusted loss of $1.02 per share, which is higher than the same quarter last year's EPS of $-1.75. Additionally, the company reported zero revenue for the quarter.

While specific operating expense data for Q4 2024 is not available, the trend of increasing losses suggests that operating expenses may have been higher in Q4 2024 compared to previous quarters, or at least not decreased significantly enough to affect the bottom line favorably. The lack of revenue contribution further implies that the company's expenses may have outpaced its revenue generation in this period.